ArticleFrontiers in cardiovascular medicine2026
Lung ultrasound B-lines, NT-proBNP, and left atrial volume Index for bedside characterization of preserved-ejection-fraction phenotype in acute heart failure: a single-center observational study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure with preserved ejection fraction (HFpEF) is often difficult to identify at the bedside because no single clinical, biochemical, or echocardiographic marker is sufficiently definitive. Lung ultrasound B-lines, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and left atrial volume index (LAVI) reflect different aspects of congestion and cardiac remodeling. This study evaluated whether combining these routinely available parameters could improve simplified bedside identification of HFpEF. Methods: This single-center prospective study included 220 patients hospitalized with acute decompensated heart failure at Xiangtan Central Hospital between January 2023 and December 2025. HFpEF was defined as left ventricular ejection fraction ≥ 50%, and patients with mildly reduced or reduced ejection fraction were classified as non-HFpEF. B-line score, NT-proBNP, LAVI, E/e', body mass index, and atrial fibrillation status were recorded. Logistic regression, receiver operating characteristic curve analysis, and decision curve analysis were used to evaluate the performance and potential clinical utility of individual markers and combined models. Results: Among 220 patients, 57 had HFpEF and 163 had non-HFpEF. Individual markers showed limited-to-moderate discriminatory ability, with AUCs of 0.680 for B-line score, 0.655 for log-transformed NT-proBNP, and 0.550 for LAVI. The three-marker model combining B-line score, log-transformed NT-proBNP, and LAVI achieved an AUC of 0.737, with a sensitivity of 71.9% and specificity of 69.3%. The full exploratory model further increased the AUC to 0.765. Decision curve analysis suggested that the combined models provided greater net benefit than treat-all and treat-none strategies across a clinically relevant range of threshold probabilities. Conclusions: A combination of lung ultrasound B-lines, NT-proBNP, and LAVI showed moderate ability to distinguish patients with a preserved-ejection-fraction phenotype from those with lower LVEF among patients with acute heart failure. This approach should be interpreted as a bedside phenotype-characterization tool rather than a validated diagnostic model for confirming HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.